All In Biotech

NDA 021055 · Bausch

Targretin

Bexarotene · Oral · Retinoid

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Sep 14, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Dec 29, 1999

Approved uses

2

Original approval plus efficacy supplements

Registered trials

46

9 Phase 3, 1 recruiting

FAERS reports

1,325

998 serious, 250 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: BIRTH DEFECTS TARGRETIN is a member of the retinoid class of drugs that is associated with birth defects in humans. Bexarotene also caused birth defects when administered orally to pregnant rats. TARGRETIN must not be administered to a pregnant woman. ( 8.1 ) WARNING: BIRTH DEFECTS See full prescribing information for complete boxed warning. TARGRETIN is a member of the retinoid class of drugs that is associated with birth defects in humans. Bexarotene also caused birth defects when administered orally to pregnant rats. TARGRETIN must not be administered to a pregnant woman. ( 8.1 )

What it is approved for

From the label in effect Apr 30, 2020.

TARGRETIN ® (bexarotene) Capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. TARGRETIN (bexarotene) is a retinoid indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. ( 1 )

Mechanism: Bexarotene selectively binds and activates retinoid X receptor subtypes (RXRα, RXRß, RXRγ). RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs), vitamin D receptor, thyroid receptor, and peroxisome proliferator activator receptors (PPARs). Once activated, these receptors function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression in vivo in...

Therapeutic areas: Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 29, 2015 Supplement 10 · Efficacy LabelLetter
  • Dec 29, 1999 Original approval · Type 1 - New Molecular Entity · priority review LabelLetterReview
1 products under this application
  • TARGRETIN · BEXAROTENE 75MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Bexarotene" as an intervention, any sponsor and status, largest first.

All 46 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective113
  • off label use77
  • death76
  • hypothyroidism75
  • hypertriglyceridaemia59
  • disease progression58
  • fatigue50
  • pruritus47
  • malignant neoplasm progression43
  • condition aggravated39
  • nausea37
  • pneumonia34

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200412
200519
200628
200727
200828
200931
201031
201133
201230
201335
201433
201570
201673
201777
201887
2019104
202097
202184
2022115
202386
202475
202588
202661

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Targretin* (Bexarotene)

2024 spending

$4.9M

Beneficiaries

47

208 claims

Per beneficiary

$103,984

$272.73 per unit

View as table
YearSpending
2020$24,085,741
2021$15,748,332
2022$13,367,911
2023$5,943,142
2024$4,887,241

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 89 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.